Excellent
Patient Risk:
Low
Summary
The AI response claim correctly reflects the FDA boxed warning and Section 5 fetal toxicity language for lisinopril and hydrochlorothiazide tablets, including the increased risk in the 2nd and 3rd trimesters and discontinuation when pregnancy is detected.
Category Scores
Accurate Statements
Renin-angiotensin system drugs (including lisinopril/ACE inhibitors) can cause fetal injury/death, especially during the 2nd and 3rd trimesters.
Boxed Warning (WARNING: FETAL TOXICITY) and Section 5 (WARNINGS) — Fetal Toxicity: reduced fetal renal function with increased fetal/neonatal morbidity and death in 2nd/3rd trimesters; associated complications described.
When pregnancy is detected, discontinue lisinopril and hydrochlorothiazide tablets as soon as possible.
Boxed Warning and Section 5 (WARNINGS) — Fetal Toxicity: instructs discontinuation when pregnancy is detected 'as soon as possible' for lisinopril and hydrochlorothiazide tablets.
Unsupported Statements
No additional statement beyond the pregnancy risk/discontinuation claim is made in the response that could be judged unsupported by the provided label excerpts.
The provided response is primarily an audit evaluation of label alignment; it does not introduce dosing/contraindication/interaction specifics not supported by the label text supplied.
Contradictions
Important Omissions
Serial ultrasound, fetal testing appropriateness, and guidance to closely observe exposed infants (hypotension, oliguria, hyperkalemia), including the 'unusual case' alternative-therapy language.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response conveys the core boxed warning and required action (discontinue when pregnancy is detected). It omits additional label-management details for exceptional scenarios and post-exposure monitoring, but omission is unlikely to directly create unsafe use beyond the already-critical instruction being present.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Primary Issue
Omission of additional label management/monitoring instructions within the fetal toxicity section (serial ultrasound, fetal testing, and infant monitoring guidance).
Suggested Improvement
Include that, if no alternative therapy exists, patients should be counseled about fetal risk and serial ultrasound should be performed; if oligohydramnios is observed, discontinue unless lifesaving, and closely observe exposed infants for hypotension, oliguria, and hyperkalemia.